A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks

(2016) Shashikant Srivastava et al.   CLINICAL INFECTIOUS DISEASES

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests

(2016) Soumya Swaminathan et al.   CLINICAL INFECTIOUS DISEASES

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

(2016) Shashikant Srivastava et al.   EBioMedicine

The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism

(2016) Zoe Rogers et al.   EBioMedicine

Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments

(2015) Jotam G. Pasipanodya et al.   CLINICAL INFECTIOUS DISEASES

Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes

(2015) Tawanda Gumbo et al.   CLINICAL INFECTIOUS DISEASES

Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm

(2015) Tawanda Gumbo et al.   CLINICAL INFECTIOUS DISEASES

Failed Pediatric Drug Development Trials

(2015) JD Momper et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Childhood tuberculosis in the United States: shifting the focus to prevention

(2015) A. T. Cruz et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis

(2015) Tawanda Gumbo et al.   JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetic-Pharmacodynamic and Dose-Response Relationships of Antituberculosis Drugs: Recommendations and Standards for Industry and Academia

(2015) Tawanda Gumbo et al.   JOURNAL OF INFECTIOUS DISEASES

The association between sterilizing activity and drug distribution into tuberculosis lesions

(2015) Brendan Prideaux et al.   NATURE MEDICINE

Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis

(2014) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous Necrotic Granulomas

(2014) Scott M. Irwin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Commentary: A targets framework: Dismantling the invisibility trap for children with drug-resistant tuberculosis

(2014) Mercedes C Becerra et al.   JOURNAL OF PUBLIC HEALTH POLICY

Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates

(2014) Helen E Jenkins et al.   LANCET

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

(2013) J. G. Pasipanodya et al.   JOURNAL OF INFECTIOUS DISEASES

Biological variability and the emergence of multidrug-resistant tuberculosis

(2013) Tawanda Gumbo   NATURE GENETICS

Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis

(2013) Christopher B Ford et al.   NATURE GENETICS

New Susceptibility Breakpoints and the Regional Variability of MIC Distribution in Mycobacterium tuberculosis Isolates

(2012) Jotam Pasipanodya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens

(2012) Shashikant Srivastava et al.   CURRENT PHARMACEUTICAL DESIGN

Tuberculosis in Children

(2012) Carlos M. Perez-Velez et al.   NEW ENGLAND JOURNAL OF MEDICINE

In SilicoChildren and the Glass Mouse Model: Clinical Trial Simulations To Identify and Individualize Optimal Isoniazid Doses in Children with Tuberculosis

(2010) Prakash M. Jeena et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future

(2010) Jotam Pasipanodya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

(2010) T. Gumbo   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY